Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
There’s intriguing news today about a technology that could improve treatment in people with Alzheimer’s. It uses sound waves ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...
Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.
Prof Sir John Hardy is chairman of molecular biology of neurological disease at the UCL Institute of Neurology - Paul Grover for the Telegraph Alzheimer’s drugs should be prescribed like statins ...